Jiangsu Hengrui Pharmaceuticals Co.,Ltd (SHA:600276)

Market Cap	398.48B
Revenue (ttm)	30.98B
Net Income (ttm)	7.47B
Shares Out	6.62B
EPS (ttm)	1.16
PE Ratio	51.71
Forward PE	39.27
Dividend	0.20 (0.33%)
Ex-Dividend Date	May 23, 2025

Volume	28,835,842
Average Volume	29,534,568
Open	60.07
Previous Close	60.00
Day's Range	59.91 - 61.38
52-Week Range	42.40 - 74.04
Beta	0.43
RSI	46.91
Earnings Date	Apr 21, 2026

About SHA:600276

Jiangsu Hengrui Pharmaceuticals Co.,Ltd, a pharmaceutical company, researches, develops, manufactures, and commercializes medicines to address unmet clinical needs in China and internationally. It develops medicines in the areas of oncology, metabolic and cardiovascular, immunological and respiratory, neuroscience, pain management, infectious, respiratory system, hematological, ophthalmology, and autoimmune and other diseases. The company was founded in 1970 and is headquartered in Lianyungang, China.

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1970
• Employees: 20,238
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600276

Financial Performance

In 2024, SHA:600276's revenue was 27.98 billion, an increase of 22.63% compared to the previous year's 22.82 billion. Earnings were 6.34 billion, an increase of 47.28%.